Search
Michigan Paid Clinical Trials
A listing of 2185 clinical trials in Michigan actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 2185
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Michigan is currently home to 2185 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Recruiting
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more li... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Northern Pines Hlth Ctr, PC, Buckley, Michigan
Conditions: Obesity
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Recruiting
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
06/10/2025
Locations: Site-015, Farmington Hills, Michigan
Conditions: Parkinson Disease
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Recruiting
This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before the study. The purpose of this study is to find out whether a medicine called vicadrostat, in combination with another medicine called empagliflozin, helps people with chronic heart failure.
In this study, participants are put into 2 groups randomly. Participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: McLaren Bay Region Medical Center, Bay City, Michigan
Conditions: Heart Failure
Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes
Recruiting
The goal of this multi-center, randomized, cross-over study is to evaluate the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 System in individuals with type 1 or type 2 diabetes.
Study participants will complete about 5 in-person visits and be expected to treat their diabetes per their usual routine using the system at the lowest available target setting.
Each participant will begin the study using either the Omnipod 5 SmartAdjust 2.0 System or the Omnipod 5 System for 4 weeks (Per... Read More
Gender:
ALL
Ages:
Between 2 years and 70 years
Trial Updated:
06/10/2025
Locations: Henry Ford, Detroit, Michigan
Conditions: Diabetes Mellitus, Type 1, Type 2
Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Recruiting
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/10/2025
Locations: Clinical Research Inst of MI, Chesterfield, Michigan
Conditions: Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Recruiting
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/10/2025
Locations: Michigan Center for Rsrch Company, Clarkston, Michigan
Conditions: Hidradenitis Suppurativa
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
Recruiting
This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA). The primary objective is to evaluate the effects of IMVT-1402 compared to placebo, as measured by the American College of Rheumatology 20% (ACR20) response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Site Number - 1021, Saint Clair Shores, Michigan
Conditions: Rheumatoid Arthritis
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Recruiting
This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Advanced Solid Tumor
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Recruiting
This study consists of two parts: phase 2 (Part A) and phase 3 (Part B). It is a multicenter study designed to evaluate the safety, effectiveness, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to assess how CSL889 affects the time it takes for VOC to resolve in participants with SCD, and to evaluate the safety and tolerabili... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/10/2025
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Sickle Cell Disease Vaso-occlusive Crisis
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Recruiting
This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
Gender:
ALL
Ages:
13 years and above
Trial Updated:
06/10/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Familial Partial Lipodystrophy
ARC101 in Advanced Solid Tumors
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Advanced Solid Tumor
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Recruiting
This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younger patients who are considered unfit for standard treatment, and who have an abnormal change (mutation) in the IDH2 gene. This gene mutation can cause AML to grow and spread. This trial is being done to see if adding enasidenib to the usual treatment can help mo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton, Michigan
Conditions: Acute Myeloid Leukemia
1 - 12 of 2185
Clinical trials vary in time; in total a single clinical trial may take up to 15 years to complete, and some longitudinal studies ask the participant to stay in touch for follow up questions for a few years after their participation in the study is finished. Depending on the goal and the design of a clinical trial, volunteers may be asked to stay on site for a set amount of nights; this happens because the researchers might want to monitor the participant's at different hours of the day or night. Some clinical research is also setup to compensate individuals, and paid clinical trials are not uncommon.
In Michigan, the University of Michigan division of research has one of the largest clinical trial and research centers in the state, where interested volunteers can enroll in studies for healthy or non-healthy individuals. The Barbara Ann Karmanos cancer institute in Detroit, Michigan also offers clinical trials for many types of cancers for both healthy and non-healthy individuals.
Volunteers who decide to participate in a clinical trial may be compensated for their time and travel expenses during their participation in the study. The compensation will vary depending on the type of study and level of participation required from the volunteer, but paid clinical trials in Michigan are very common.
Participating in a clinical trial is always completely voluntary. This means that nobody, regardless of their condition can be forced to participate nor can they be forced to continue participating in a trial if they wish to withdraw from the study. Non-healthy individuals who decide to enroll in a clinical trial after a suggestion from their doctor or to try an experimental treatment for their condition will never be denied care if they decide to drop out of the study.
Search Clinical Trials in Michigan by Condition
See All Conditions